Clinical trial · Interventional
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy: a Phase III Randomized, Controlled Clinical Trial
NCT06559696CI-TRIAL-00080518recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to explore the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients (ypN+or supra/subclavicular lymph node positive) after neoadjuvant chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| internal mammary nodal irradiation | Radiation | — | UNRESOLVED |
| No internal mammary node irradiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- internal mammary nodal irradiation
- description
- chest wall/whole breast and supraclavicular+-axillary nodal plus internal mammary nodal irradiation
- interventionNames
- Radiation: internal mammary nodal irradiation
- type
- ACTIVE_COMPARATOR
- label
- No internal mammary node irradiation
- description
- chest wall/whole breast and supraclavicular+-axillary nodal irradiation
- interventionNames
- Radiation: No internal mammary node irradiation
Primary outcomes (1)
- measure
- Disease free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed invasive breast cancer * Underwent neoadjuvant chemotherapy * Eastern Cooperative Oncology Group Performance Status Scale 0-2 * ypN+ after neoadjuvant chemotherapy or supraclavicular/subclavicular lymph node metastasis before system therapy * No distant metastases * No internal mammary nodes metastases based on images before system therapy * Willing to follow up * Written,informed consent Exclusion Criteria: * Without neoadjuvant chemotherapy * Distant metastases * Simultaneous bilateral breast cancer * Pathological confirmation or imaging consideration of lymph node metastasis in the internal mammary before system therapy * Had simultaneous or previous secondary malignancies, except for non-malignant melanoma skin cancer, papillary thyroid / follicular carcinoma, cervical carcinoma in situ, contralateral non-invasive breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.